EUS-guided radiofrequency ablation for pancreatic tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the safety and effectiveness of EUS-guided radiofrequency ablation (RFA) for treating solid pancreatic neoplasms in patients who are not suitable for surgery. The procedure involves using a high-frequency alternating current to generate heat, leading to tissue destruction and potential tumor reduction. Conducted at multiple high-volume international institutions, the study aims to assess adverse events, technical success, and survival rates among participants. Patients with pancreatic neuroendocrine tumors or pancreatic ductal carcinoma under 5 cm will be recruited for this innovative treatment approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years-old or above
* Suffering from pancreatic neuroendocrine tumor or pancreatic ductal carcinoma (\<5cm in largest diameter) that was confirmed by fine needle aspiration cytology
* Unsuitable for surgery, due to one (or more) of the following items:

  * ASA score \> II\*
  * An alternative advanced malignancy
  * Unsuitable for surgery upon expert's opinion for any other reason
* Healthy individuals who are not keen for surgical resection
* Eligible for endoscopic intervention
* Written informed consent

Exclusion Criteria:

* Coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count \<50,000x103/uL
* Pregnancy
* Patients with a poor mental condition or mental retardation, unable to understand the nature and possible consequences of the study
* Patients unwilling to undergo follow-up assessments
* Patients with liver cirrhosis, portal hypertension and/or gastric varices.

Where it's running

• Department of Surgery, Prince of Wales Hospital
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Anthony YB Teoh, Professor — Chinese University of Hong Kong
• Study coordinator: Anthony YB Teoh, Professor
• Email: anthonyteoh@surgery.cuhk.edu.hk
• Phone: 26322956

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Energy needs after pancreatic surgery: measuring metabolism to guide nutrition

  This study tests how much energy patients need after pancreatic surgery and compares direct measurements with common estimating methods to see if standard formulas are accurate.

  Recruiting Evangelismos Hospital · Athens, Attica · NCT07703813

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• Indocyanine green–guided laparoscopic distal pancreatectomy vs standard approach for pancreatic body/tail lesions

  This trial tests whether using indocyanine green (ICG) fluorescence during laparoscopic distal pancreatectomy helps surgeons protect blood flow and structures, compared with the standard approach, in adults with pancreatic body or tail tumors.

  Recruiting Alexandria University · Alexandria · NCT07656571

• Pancreatic Surgery and New Diabetes Risk in Adults without Diabetes

  This study tests whether removing part or all of the pancreas during surgery affects blood sugar control and metabolism in adults who did not have diabetes before the operation.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT07608055

• Pancreatic Cancer Screen Test in Japan Using the Enzeavour Blood Assay

  This nationwide screening study in Japan tests the Enzeavour Pancreatic Cancer blood test in about 10,000 asymptomatic adults to see if it can help detect pancreatic cancer early.

  Recruiting at 69 sites Cosomil, Inc. · Nagakute, Aichi-ken and 68 other locations · NCT07605819

• NEO-Match nanomechanical testing of pancreatic tumor samples

  This will test whether the NEO-Match® nanomechanical test on biopsy tissue can help predict response to pre-surgery treatment and detect cancer in people with suspected pancreatic tumors.

  Recruiting Artidis Ag · Tampa, Florida · NCT07542041

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.